Non Muscle Invasive Bladder Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Non Muscle Invasive Bladder Cancer Pipeline Report
• DelveInsight's Non-Muscle Invasive Bladder Cancer pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Non Muscle Invasive Bladder Cancer treatment.
• The leading Non-Muscle Invasive Bladder Cancer Companies working in the market include Prokarium Ltd, Vaxiion Therapeutics, Tyra Biosciences, Lipac Oncology, SURGE Therapeutics, Jiangsu Simcere Pharmaceutical, Shanghai Hengrui Pharmaceutical Co., enGene, and others.
• Promising Non Muscle Invasive Bladder Cancer Therapies in the various stages of development include CG0070, n-dodecyl-B-D-maltoside, Durvalumab, BCG, cis-UCA solution, and others.
• May 2024:- Protara Therapeutics- A Phase 2, Open-Label Study to Evaluate Safety and Anti-Tumor Activity, of Intravesical Instillation of TARA-002 in Adults With High-Grade Non-Muscle Invasive Bladder Cancer. The purpose of this Phase 2 study (TARA-002-101-Ph2) is to further assess the safety and anti-tumor activity of TARA-002 at the RP2D which has been established in the Phase 1a dose finding study (TARA-002-101-Ph1a).
• May 2024:- AstraZeneca- A Phase IIIb Open-Label, Single-Arm, Multi-Center, US Study of Bacillus Calmette-Guerin (BCG) Administered in Combination With Durvalumab in Adult BCG-naïve, High-risk Non-Muscle- Invasive Bladder Cancer Participants (PATAPSCO). The purpose of this study is to assess the safety, tolerability, and efficacy profile of durvalumab + BCG (induction and maintenance) combination therapy in adult United States participants with a histologically confirmed diagnosis of high-risk non-muscle-invasive bladder cancer (NMIBC), who have received no prior systemic therapy for NMIBC, and who are BCG-naïve.
• May 2024:- Merck Sharp & Dohme LLC- A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) That is Either Persistent or Recurrent Following BCG Induction or That is Naïve to BCG Treatment (KEYNOTE-676).
• May 2024:- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins- Phase 2 Window of Opportunity Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors. This phase II trial studies how well Pemigatinib (an orally administered inhibitor of fibroblast growth factor receptors 1, 2, and 3) works in non-muscle invasive bladder cancer (NMIBC) patients with recurrent tumors and a prior history of low- or intermediate-risk NMIBC tumors. Participants will receive pemigatinib for 4-6 weeks prior to standard of care transurethral resection of bladder tumor (TURBT).
• May 2024:- Astellas Pharma Global Development Inc.- A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC). This study will test a drug called enfortumab vedotin in participants with a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC). This study will also evaluate what the side effects are and if the drug works to treat NMIBC. A side effect is anything a drug does to your body besides treating your disease. In this study enfortumab vedotin will be put into the bladder using a catheter. A catheter is a thin tube that can be put into your bladder.

Request a sample and discover the recent advances in Non Muscle Invasive Bladder Cancer Treatment Drugs @ Non Muscle Invasive Bladder Cancer Pipeline Outlook Report- https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Non Muscle Invasive Bladder Cancer Overview
Non muscle-invasive bladder cancer (NMIBC) is a heterogeneous sub classification of urothelial carcinoma with significant variation in individual risk of recurrence and progression to muscle-invasive disease. It is a cancer found in the tissue that lines the inner surface of the bladder. Some people may have symptoms that suggest they have bladder cancer. Others may feel nothing at all. Some symptoms should never be ignored. Some of the common symptoms are hematuria (blood in the urine) - the most common symptom, often without pain, frequent and urgent urination, pain when urine passes, pain in lower abdomen, and back pain.

Non Muscle Invasive Bladder Cancer Emerging Drugs Profile

• TAR-200: TARIS Biomedical
TAR-200 is an investigational targeted releasing system enabling controlled release of gemcitabine into the bladder, sustaining local drug exposure for weeks at a time. The safety and efficacy of TAR-200 are being evaluated in Phase II and Phase III studies in patients with muscle-invasive bladder cancer in SunRISe-2 and SunRISe-4 and NMIBC in SunRISe-1 and SunRISe-3. Currently, the drug is in Phase III stage of its clinical trial for the treatment of non muscle invasive bladder cancer.

• VAX 014: Vaxiion Therapeutics
VAX014 is a novel rBMC-based oncolytic immunotherapy designed to have distinct advantages over traditional and emerging oncolytic virotherapies. VAX014's ability to specifically target both alpha3beta1(α3β1) and alpha5beta1 (α5β1) integrins facilitates broad spectrum activity against various solid tumor types because these two integrin family members are clinically validated as being selectively expressed or overexpressed in a wide variety of solid tumor indications (and most mouse models). Currently, the drug is in the Phase I stage of its development for the treatment of Non muscle-invasive bladder cancer.

• SIM0237: Simcere Pharmaceutical Group
SIM0237 is an anti-PD-L1 monoclonal antibody fused with potency-reduced IL-15/IL-15Rα sushi domain developed in-house by utilizing Simcere Zaiming's protein engineering platform. As a bifunctional protein, the compound can block the PD-1/PD-L1 immunosuppressive pathway via binding to PD-L1 and activate the immune system through its IL-15 part, thus playing a synergistic role of relieving immunosuppression and boosting the immune activation to exhibit antitumor effect. The attenuated IL-15 part of SIM0237 increases MTD and avoids overstimulation and accompanied anergy of NK and CD8+ T cells. In the meantime, fusion of attenuated IL-15 to full anti-PD-L1 mAb further enhances the half-life of attenuated IL-15 and delivers IL-15 directly to the tumor microenvironment avoiding notorious CRS toxicity induced by systemic IL-15 exposure. Currently, the drug is in Phase I stage of its clinical trial for the treatment of non-muscle invasive bladder cancer.

Find out more about Non Muscle Invasive Bladder Cancer Treatment Drugs @ Drugs for Non Muscle Invasive Bladder Cancer Treatment- https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Non Muscle Invasive Bladder Cancer Therapeutics Assessment
There are approx. 20+ key companies which are developing the therapies for Non Muscle Invasive Bladder Cancer. The companies which have their Non Muscle Invasive Bladder Cancer drug candidates in the most advanced stage, i.e. Phase III include, TARIS Biomedical.

DelveInsight's Non Muscle Invasive Bladder Cancer pipeline report covers around 25+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Discover more about Non Muscle Invasive Bladder Cancer in development @ Non Muscle Invasive Bladder Cancer Clinical Trials- https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Non Muscle Invasive Bladder Cancer Companies
Prokarium Ltd, Vaxiion Therapeutics, Tyra Biosciences, Lipac Oncology, SURGE Therapeutics, Jiangsu Simcere Pharmaceutical, Shanghai Hengrui Pharmaceutical Co., enGene, and others.

Non Muscle Invasive Bladder Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Non Muscle Invasive Bladder Cancer Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

To know more about Non Muscle Invasive Bladder Cancer, visit @ Non Muscle Invasive Bladder Cancer Segmentation- https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Non Muscle Invasive Bladder Cancer Pipeline Report
• Coverage- Global
• Non Muscle Invasive Bladder Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Non Muscle Invasive Bladder Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Non Muscle Invasive Bladder Cancer Companies- Prokarium Ltd, Vaxiion Therapeutics, Tyra Biosciences, Lipac Oncology, SURGE Therapeutics, Jiangsu Simcere Pharmaceutical, Shanghai Hengrui Pharmaceutical Co., enGene, and others.
• Non Muscle Invasive Bladder Cancer Therapies- CG0070, n-dodecyl-B-D-maltoside, Durvalumab, BCG, cis-UCA solution, and others.

For further information on the Non Muscle Invasive Bladder Cancer Pipeline Therapeutics, reach out @ Non Muscle Invasive Bladder Cancer Products Development- https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Non Muscle Invasive Bladder Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Non Muscle Invasive Bladder Cancer- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. TAR-200: TARIS Biomedical
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug name: Company name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. VAX 014: Vaxiion Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Non Muscle Invasive Bladder Cancer Key Companies
21. Non Muscle Invasive Bladder Cancer Key Products
22. Non Muscle Invasive Bladder Cancer- Unmet Needs
23. Non Muscle Invasive Bladder Cancer- Market Drivers and Barriers
24. Non Muscle Invasive Bladder Cancer- Future Perspectives and Conclusion
25. Non Muscle Invasive Bladder Cancer Analyst Views
26. Non Muscle Invasive Bladder Cancer Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.